About Spark Impact
Spark Impact, established in 2011, is a private debt fund primarily based in Chester, United Kingdom. It specializes in financing Seed round of companies based in United Kingdom. Its portfolio includes 22 firms, spanning the Life Sciences, High Tech sectors.
As of Oct 2026, Spark Impact has witnessed 1 portfolio exit so far. Its most notable investments include companies like Alderley Analytical, Cytox and ASep Healthcare.
Its latest investment was a $376K Seed round in Absynth Biologics on Nov 30, 2015, which also saw participation from Alderley Park Ventures and Fusion IP.
Key Metrics
Founded Year
2011
Location
Chester, United Kingdom
Portfolio Companies
Sectors of Investment
Stages of Investment
Seed & Series A
Locations of Investment
Spark Impact's List of Top Investments
Spark Impact has a portfolio of 22 companies. Their most notable investmentis in CytoxTheir portfolio spans across and United Kingdom. They have invested in Life Sciences, High Tech, Healthcare, across Seed, Series A stages. Here is the list of top investments by Spark Impact:
Provider of bioanalytical services for drug development programs and testing. The organization supports projects involving small molecules, peptides, oligonucleotides, and large molecules. It offers method validation and delivers results according to regulatory guidelines. Services include preclinical and clinical bioanalysis, immunogenicity, biomarker analysis, and sample storage. The company utilizes mass spectrometry and ligand binding assays.
Key facts about Alderley Analytical
- Founded Year: 2013
- Location: Stockport (United Kingdom)
- Stage: Acquired
- Total Funding till date: $869K
- Employee Count: 18 as on Sep 30, 2026
- Investors: Pioneer Group, Northwest Fund and 3 Others
- Latest Funding Round: Seed, Jun 05, 2018, $*****
- Highlight: Acquired
2. Cytox
Developer for prognostic tests for assessing the risk of dementia. It is investigating SNP targets in the mTOR pathway to predict and diagnose mild cognitive impairment, which is considered to be an early indicator of dementia and Alzheimer's disease. The company has two products genoSCORE LAB and genoTOR that use blood and saliva for diagnostic approaches.
Key facts about Cytox
- Founded Year: 2007
- Location: Oxford (United Kingdom)
- Stage: Series B
- Total Funding till date: $12.1M
- Employee Count: 1 as on Sep 30, 2026
- Investors: Origin Capital, Masa Life Science Fund and 22 Others
- Latest Funding Round: Series B, Aug 07, 2019, $*****
_1551938371537.png?format=webp&height=120&width=120){kind=logo}
ASep Healthcares has developed tourniquets. It is a compressing device used to control arterial and venous blood flow. This helps in one-handed operation for blood draws.
Key facts about ASep Healthcare
- Founded Year: 2008
- Location: Liverpool (United Kingdom)
- Valuation: $*****
- Stage: Seed
- Total Funding till date: $186K
- Employee Count: 7 as on Sep 30, 2026
- Investors: Northwest Fund, Imperial Innovations and 1 Other
- Latest Funding Round: Seed, Feb 19, 2013, $*****
4. Videregen
Videregen, a Northwick Park Institute spin-out, develops autologous replacement organs for transplant. The company decellularizes donor organs using detergents and enzymes to remove all cells and DNA, leaving behind only a scaffold made of collagen, elastin and glycosamineglycans. This scaffold is then 'reseeded' with autologous stem cells derived from the patient to prevent immune response against the transplanted organ. Videregen is exploring organ replacements for trachea, small bowel, and liver.
Key facts about Videregen
- Founded Year: 2012
- Location: Liverpool (United Kingdom)
- Stage: Seed
- Total Funding till date: $2.59M
- Employee Count: 8 as on Mar 31, 2022
- Investors: Invictus Capital Partners, Epiphany Capital and 31 Others
- Latest Funding Round: Grant (prize money), Jan 01, 2016, $*****
Developer of vaccines and antibodies to treat bacterial infections. The company has established a vaccine pipeline targeting the pathogens Staphylococcus aureus, Clostridium difficile, and Streptococcus pyogenes. Also developing monoclonal antibodies that specifically recognize S. aureus.
Key facts about Absynth Biologics
- Founded Year: 2007
- Location: Sheffield (United Kingdom)
- Annual Revenue: £0 - £1M as on Jul 31, 2015
- Last Known Valuation: $*****
- Stage: Deadpooled
- Total Funding till date: $3.81M
- Employee Count: 3 as on Aug 31, 2019
- Investors: IP Group, o2h group and 5 Others
- Latest Funding Round: Seed, Apr 11, 2017, $*****
Spark Impact's Investments by Stage
Spark Impact has made 6 investments in Seed stage with an average round size of $627K and 2 investments in Series A stage with an average round size of $2.62M.Stage of entry | No. of Investments |
|---|---|
Seed | 6 |
Series A | 2 |
Note: We have considered here, only first round of investments
Spark Impact's Investments by Sector
Spark Impact has a diverse portfolio, with companies operating in the Life Sciences, Healthcare, High Tech and Sustainability Tech. Notably, it has invested in 15 Enterprise (B2B) companies, 12 Tech companies, 5 Software companies and at least 3 companies focusing on Social impact.Sector | No. of Investments |
|---|---|
Life Sciences | 6 |
Healthcare | 1 |
High Tech | 1 |
Sustainability Tech | 1 |
Note: We have considered here, only first round of investments
Spark Impact's Investments by Geography
Spark Impact has made most investments in United Kingdom (8).Spark Impact's recent investments
Spark Impact has not made any investment in 2026 so far.Here are the most recent investments by Spark Impact:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Nov 30, 2015 | United Kingdom | Seed | 4865 | ||
Jul 21, 2015 | United Kingdom | Seed | 1496 | - | |
May 05, 2015 | United Kingdom | Seed | 4141 | - | |
Feb 05, 2015 | United Kingdom | Seed | 3456 | - | |
Sep 25, 2014 | United Kingdom | Seed | 3239 |
Acquired companies in Spark Impact's Portfolio
1 company from Spark Impact's portfolio has been acquired. The most recent acquisition was Alderley Analytical in Oct 2024 by Synexa Life Sciences for $*****.Here are Spark Impact's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 07, 2024 | - | - | 8692 |
Co-investors of Spark Impact
Over the past 14 years, 20 investors have co-invested in Spark Impact's portfolio companies. This includes funds and angels.
- Invested before Spark Impact: Masa Life Science Fund, Northwest Fund and 1 other have invested in rounds before Spark Impact. There is 1 company where Masa Life Science Fund has invested before Spark Impact and 1 company where Northwest Fund has invested before Spark Impact.
- Top Co-investors of Spark Impact: 7 investors entered a company along with Spark Impact. These include investors like Northwest Fund (1 company).
- Invested after Spark Impact: A total of 10 investors have invested in Spark Impact's portfolio after their investments. Top Investors include Europa (2 companies) and EIC Fund (1 company).
Recent News related to Spark Impact
•
•
•
£250,000 investment for vaccine research firm - Manchester Evening NewsManchestereveningnews•Nov 30, 2015•Absynth Biologics, Spark Impact
•
Significant £1.2m investment round for Videregen - Videregen Videregen•Sep 25, 2014•Videregen, Spark Impact, London Business Angels
•
